Infant Bacterial Therapeutics AB (publ)

OM:IBT B 株式レポート

時価総額:SEK 514.6m

Infant Bacterial Therapeutics マネジメント

マネジメント 基準チェック /24

Infant Bacterial Therapeuticsの CEO はStaffan Strombergで、 Jan2013年に任命され、 の在任期間は 11.83年です。 の年間総報酬はSEK 5.33Mで、 57.9%給与と42.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.79%を直接所有しており、その価値はSEK 4.08M 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と7.5年です。

主要情報

Staffan Stromberg

最高経営責任者

SEK 5.3m

報酬総額

CEO給与比率57.9%
CEO在任期間11.8yrs
CEOの所有権0.8%
経営陣の平均在職期間1.5yrs
取締役会の平均在任期間7.5yrs

経営陣の近況

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

CEO報酬分析

Infant Bacterial Therapeutics の収益と比較して、Staffan Stromberg の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-SEK 144m

Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Sep 30 2018n/an/a

-SEK 26m

Jun 30 2018n/an/a

-SEK 22m

Mar 31 2018n/an/a

-SEK 37m

Dec 31 2017SEK 3mSEK 1m

-SEK 36m

報酬と市場: Staffanの 総報酬 ($USD 482.38K ) は、 Swedish市場 ($USD 235.48K ) の同規模の企業の平均を上回っています。

報酬と収益: Staffanの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Staffan Stromberg (57 yo)

11.8yrs

在職期間

SEK 5,327,000

報酬

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Staffan Stromberg
Chief Executive Officer11.8yrsSEK 5.33m0.79%
SEK 4.1m
Maria Ekdahl
Chief Financial Officer2.2yrsデータなし0.035%
SEK 179.8k
Anders Kronström
Chief Operating Officer6.8yrsSEK 500.00k0.083%
SEK 427.6k
Thomas Schnitzer
Chief Scientific Officerless than a yearデータなしデータなし
Sanjiv Sharma
Head of Medical Affairsless than a yearデータなしデータなし
Jonas Rastad
Chief Medical Officerless than a yearデータなしデータなし

1.5yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: IBT Bの経営陣は 経験豊富 とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Peter Rothschild
Chairman13.8yrsSEK 727.00kデータなし
Margareta Hagman
Independent Director9.2yrsSEK 153.00k0.039%
SEK 201.8k
Eva Idén
Independent Director7.5yrsSEK 153.00k0.0042%
SEK 21.4k
Kristina Nygren
Independent Director6.5yrsSEK 153.00k0.00074%
SEK 3.8k
Anthon Jahreskog
Independent Director7.5yrsSEK 193.00k0.18%
SEK 927.1k

7.5yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: IBT Bの 取締役会経験豊富 であると考えられます ( 7.5年の平均在任期間)。